肿瘤细胞治疗研究
英文原题：Claudin18.2 as a Promising Therapeutic Target in Gastric Cancer.
Claudin-18.2（CLDN18.2）是紧密连接蛋白的一种亚型，已成为胃癌（GC）中有前景的治疗靶点。
Claudin-18.2（CLDN18.2）是紧密连接蛋白的一种亚型，已成为胃癌（GC）有前景的治疗靶点。CLDN18.2负责维持胃部稳态，并保护上皮细胞免受低pH环境损伤。有意思的是，CLDN18.2的表达严格局限于胃组织，因此是理想的肿瘤标志物。本叙述性综述介绍了claudin 18.2（CLDN18.2）作为胃癌潜在生物标志物及临床治疗靶点的特征与作用，重点讨论靶向CLDN18.2的药物和疗法，包括单克隆抗体（如Zolbetuximab、Osemitamab、ZL-1211）、双特异性抗体以及CAR-T细胞免疫疗法。我们还总结了全球正在开展的多项评估CLDN18.2胃癌治疗靶点价值的临床试验。关键在于，临床前和临床数据均显示这些疗法具有较高的疗效和安全性。
Claudin-18.2 (CLDN18.2) is an isoform of a tight junction protein and has emerged as a promising therapeutic target in gastric cancer (GC). CLDN18.2 is responsible for gastric homeostasis and protects epithelial cells from low pH conditions. Interestingly, CLDN18.2 expression is strictly restricted to the stomach, making it an ideal tumor marker. This narrative review presents the characterization and role of claudin 18.2 (CLDN18.2) as a promising biomarker in GC and a target for clinical therapies, more specifically CLDN18.2-targeted drugs and therapies including mABs (e.g., Zolbetuximab, Osemitamab, ZL-1211), bsAB, and CAR-T cell-based immunotherapies. We also summarize numerous ongoing worldwide clinical trials that are evaluating CLDN18.2 as a target for GC treatment. What seems to be crucial is that preclinical and clinical data indicate their high efficacy and safety.
MEMBER ACCOUNT
登录成功会直接打开下一页。
